<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutrients</journal-id><journal-id journal-id-type="iso-abbrev">Nutrients</journal-id><journal-id journal-id-type="publisher-id">nutrients</journal-id><journal-title-group><journal-title>Nutrients</journal-title></journal-title-group><issn pub-type="epub">2072-6643</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28333093</article-id><article-id pub-id-type="pmc">5409660</article-id><article-id pub-id-type="doi">10.3390/nu9040321</article-id><article-id pub-id-type="publisher-id">nutrients-09-00321</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Effect of Regular Intake of Dry-Cured Ham Rich in Bioactive Peptides on Inflammation, Platelet and Monocyte Activation Markers in Humans</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Martínez-Sánchez</surname><given-names>Sara María</given-names></name><xref ref-type="aff" rid="af1-nutrients-09-00321">1</xref></contrib><contrib contrib-type="author"><name><surname>Minguela</surname><given-names>Alfredo</given-names></name><xref ref-type="aff" rid="af2-nutrients-09-00321">2</xref></contrib><contrib contrib-type="author"><name><surname>Prieto-Merino</surname><given-names>David</given-names></name><xref ref-type="aff" rid="af3-nutrients-09-00321">3</xref></contrib><contrib contrib-type="author"><name><surname>Zafrilla-Rentero</surname><given-names>María Pilar</given-names></name><xref ref-type="aff" rid="af1-nutrients-09-00321">1</xref></contrib><contrib contrib-type="author"><name><surname>Abellán-Alemán</surname><given-names>José</given-names></name><xref ref-type="aff" rid="af1-nutrients-09-00321">1</xref></contrib><contrib contrib-type="author"><name><surname>Montoro-García</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="af1-nutrients-09-00321">1</xref><xref rid="c1-nutrients-09-00321" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-nutrients-09-00321"><label>1</label>Cátedra de Riesgo Cardiovascular y Departamento de Nutrición, Facultad de Ciencias de la Salud, UCAM Universidad Católica San Antonio de Murcia, Campus de los Jerónimos, s/n, Guadalupe, 30107 Murcia, Spain; <email>smsanchez@ucam.edu</email> (S.M.M.-S.); <email>mpzafrilla@ucam.edu</email> (M.P.Z.-R.); <email>jabellan@ucam.edu</email> (J.A.-A.)</aff><aff id="af2-nutrients-09-00321"><label>2</label>Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB-Arrixaca), Murcia, Spain; Servicio de Inmunología, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain; <email>alfredo.minguela@carm.es</email></aff><aff id="af3-nutrients-09-00321"><label>3</label>Cátedra de Estadística “Big data”, UCAM Universidad Católica San Antonio de Murcia, 30007 Murcia, Spain; <email>dprieto@ucam.edu</email></aff><author-notes><corresp id="c1-nutrients-09-00321"><label>*</label>Correspondence: <email>smontoro@ucam.edu</email>; Tel.: +34-968-278638</corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2017</year></pub-date><volume>9</volume><issue>4</issue><elocation-id>321</elocation-id><history><date date-type="received"><day>29</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>© 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><italic><offsets xml_i="4246" xml_f="4265" txt_i="11" txt_f="30">Background and aims</offsets></italic><offsets xml_i="4274" xml_f="4630" txt_i="30" txt_f="386">: Dietary studies have shown that active biopeptides provide protective health benefits, although the mediating pathways are somewhat uncertain. To throw light on this situation, we studied the effects of consuming Spanish dry-cured ham on platelet function, monocyte activation markers and the inflammatory status of healthy humans with pre-hypertension. </offsets><italic><offsets xml_i="4638" xml_f="4645" txt_i="386" txt_f="393">Methods</offsets></italic><offsets xml_i="4654" xml_f="5437" txt_i="393" txt_f="1170">: Thirty-eight healthy volunteers with systolic blood pressure of &gt;125 mmHg were enrolled in a two-arm crossover randomized controlled trial. Participants received 80 g/day dry-cured pork ham of &gt;11 months proteolysis or 100 g/day cooked ham (control product) for 4 weeks followed by a 2-week washout before “crossing over” to the other treatment for 4 more weeks. Soluble markers and cytokines were analyzed by ELISA. Platelet function was assessed by measuring P-selectin expression and PAC-1 binding after ADP (adenosine diphosphate) stimulation using whole blood flow cytometry. Monocyte markers of the pathological status (adhesion, inflammatory and scavenging receptors) were also measured by flow cytometry in the three monocyte subsets after the interventional period. </offsets><italic><offsets xml_i="5445" xml_f="5452" txt_i="1170" txt_f="1177">Results</offsets></italic><offsets xml_i="5461" xml_f="5627" txt_i="1177" txt_f="1343">: The mean differences between dry-cured ham and cooked ham followed by a time period adjustment for plasmatic P-selectin and interleukin 6 proteins slightly failed (</offsets><italic><offsets xml_i="5635" xml_f="5636" txt_i="1343" txt_f="1344">p</offsets></italic><offsets xml_i="5645" xml_f="5658" txt_i="1344" txt_f="1357"> = 0.062 and </offsets><italic><offsets xml_i="5666" xml_f="5667" txt_i="1357" txt_f="1358">p</offsets></italic><offsets xml_i="5676" xml_f="5737" txt_i="1358" txt_f="1419"> = 0.049, respectively), notably increased for MCP-1 levels (</offsets><italic><offsets xml_i="5745" xml_f="5746" txt_i="1419" txt_f="1420">p</offsets></italic><offsets xml_i="5755" xml_f="5991" txt_i="1420" txt_f="1656"> = 0.023) while VCAM-1 was not affected. Platelet function also decreased after ADP stimulation. The expression of adhesion and scavenging markers (ICAM1R, CXCR4 and TLR4) in the three subsets of monocytes was significantly higher (all </offsets><italic><offsets xml_i="5999" xml_f="6000" txt_i="1656" txt_f="1657">p</offsets></italic><offsets xml_i="6009" xml_f="6022" txt_i="1657" txt_f="1667"> &lt; 0.05). </offsets><italic><offsets xml_i="6030" xml_f="6041" txt_i="1667" txt_f="1678">Conclusions</offsets></italic><offsets xml_i="6050" xml_f="6393" txt_i="1678" txt_f="2021">: The regular consumption of biopeptides contained in the dry-cured ham but absent in cooked ham impaired platelet and monocyte activation and the levels of plasmatic P-selectin, MCP-1 and interleukin 6 in healthy subjects. This study strongly suggests the existence of a mechanism that links dietary biopeptides and beneficial health effects.</offsets></p></abstract><kwd-group><kwd>dry-cured ham</kwd><kwd>active biopeptides</kwd><kwd>molecular markers</kwd><kwd>inflammation</kwd><kwd>platelet function</kwd><kwd>monocyte</kwd></kwd-group></article-meta></front><body><sec id="sec1-nutrients-09-00321"><title><offsets xml_i="6652" xml_f="6667" txt_i="2029" txt_f="2044">1. Introduction</offsets></title><p><offsets xml_i="6678" xml_f="6872" txt_i="2045" txt_f="2239">The food industry sector is well aware of the well-documented positive effects of functional foods or nutraceuticals on diverse physiological functions, apart from their nutritional properties [</offsets><xref rid="B1-nutrients-09-00321" ref-type="bibr"><offsets xml_i="6922" xml_f="6923" txt_i="2239" txt_f="2240">1</offsets></xref><offsets xml_i="6930" xml_f="7296" txt_i="2240" txt_f="2606">]. Improvements in diet and lifestyle to reduce or prevent specific pathological processes such as cardiovascular disease (CVD) have become a goal amongst the general public. Within the last decade, significant improvements in biomarkers related to CV health following the consumption of nutraceuticals—particularly biopeptides—have been described in animal models [</offsets><xref rid="B2-nutrients-09-00321" ref-type="bibr"><offsets xml_i="7346" xml_f="7347" txt_i="2606" txt_f="2607">2</offsets></xref><offsets xml_i="7354" xml_f="7355" txt_i="2607" txt_f="2608">,</offsets><xref rid="B3-nutrients-09-00321" ref-type="bibr"><offsets xml_i="7405" xml_f="7406" txt_i="2608" txt_f="2609">3</offsets></xref><offsets xml_i="7413" xml_f="7414" txt_i="2609" txt_f="2610">,</offsets><xref rid="B4-nutrients-09-00321" ref-type="bibr"><offsets xml_i="7464" xml_f="7465" txt_i="2610" txt_f="2611">4</offsets></xref><offsets xml_i="7472" xml_f="7474" txt_i="2611" txt_f="2613">].</offsets></p><p><offsets xml_i="7481" xml_f="7863" txt_i="2614" txt_f="2996">Cardiovascular disease is the leading cause of human mortality and complications worldwide. Hypertension is a well-known clinical risk factor for CVD. Cross-talk between platelets and monocytes is regarded as a crucial pathophysiological mechanism linking thrombosis and inflammation and is believed to mediate, at least in part, the pro-inflammatory action of activated platelets [</offsets><xref rid="B5-nutrients-09-00321" ref-type="bibr"><offsets xml_i="7913" xml_f="7914" txt_i="2996" txt_f="2997">5</offsets></xref><offsets xml_i="7921" xml_f="8020" txt_i="2997" txt_f="3096">]. Experimental data have found that activated platelets enhance cytokine production by monocytes [</offsets><xref rid="B6-nutrients-09-00321" ref-type="bibr"><offsets xml_i="8070" xml_f="8071" txt_i="3096" txt_f="3097">6</offsets></xref><offsets xml_i="8078" xml_f="8193" txt_i="3097" txt_f="3212">] as well as their receptor expression (ICAM-1R and VCAM-1R) and increase their adhesion to the blood vessel wall [</offsets><xref rid="B7-nutrients-09-00321" ref-type="bibr"><offsets xml_i="8243" xml_f="8244" txt_i="3212" txt_f="3213">7</offsets></xref><offsets xml_i="8251" xml_f="8760" txt_i="3213" txt_f="3722">]. However, the importance of monocytes/platelet phenotypical changes in human inflammatory pathophysiology and hypertension remains unclear. Besides, there is limited data on the nutraceuticals effects on inflammatory cells in humans. On the other hand, nutraceuticals such as biopeptides, sterols or polyphenols have been shown to display activities that are beneficial to CV health in humans in terms of blood pressure (BP), lipid metabolism and absorption, oxidative stress, inflammation and haemostasis [</offsets><xref rid="B8-nutrients-09-00321" ref-type="bibr"><offsets xml_i="8810" xml_f="8811" txt_i="3722" txt_f="3723">8</offsets></xref><offsets xml_i="8818" xml_f="8819" txt_i="3723" txt_f="3724">,</offsets><xref rid="B9-nutrients-09-00321" ref-type="bibr"><offsets xml_i="8869" xml_f="8870" txt_i="3724" txt_f="3725">9</offsets></xref><offsets xml_i="8877" xml_f="8878" txt_i="3725" txt_f="3726">,</offsets><xref rid="B10-nutrients-09-00321" ref-type="bibr"><offsets xml_i="8929" xml_f="8931" txt_i="3726" txt_f="3728">10</offsets></xref><offsets xml_i="8938" xml_f="8939" txt_i="3728" txt_f="3729">,</offsets><xref rid="B11-nutrients-09-00321" ref-type="bibr"><offsets xml_i="8990" xml_f="8992" txt_i="3729" txt_f="3731">11</offsets></xref><offsets xml_i="8999" xml_f="9099" txt_i="3731" txt_f="3831">]. The potential health benefits of food-derived bioactive peptides have been extensively reviewed [</offsets><xref rid="B12-nutrients-09-00321" ref-type="bibr"><offsets xml_i="9150" xml_f="9152" txt_i="3831" txt_f="3833">12</offsets></xref><offsets xml_i="9159" xml_f="9160" txt_i="3833" txt_f="3834">,</offsets><xref rid="B13-nutrients-09-00321" ref-type="bibr"><offsets xml_i="9211" xml_f="9213" txt_i="3834" txt_f="3836">13</offsets></xref><offsets xml_i="9220" xml_f="9222" txt_i="3836" txt_f="3838">].</offsets></p><p><offsets xml_i="9229" xml_f="9615" txt_i="3839" txt_f="4225">Bioactive peptides are short sequences of 2–20 amino acid long residues that are absorbed through the intestine and distributed through the circulation to produce a local or systemic physiological effect. These peptides are released during food manufacturing, for instance important biochemical changes occur with the curing of meat, including intense proteolysis by muscle peptidases [</offsets><xref rid="B14-nutrients-09-00321" ref-type="bibr"><offsets xml_i="9666" xml_f="9668" txt_i="4225" txt_f="4227">14</offsets></xref><offsets xml_i="9675" xml_f="9676" txt_i="4227" txt_f="4228">,</offsets><xref rid="B15-nutrients-09-00321" ref-type="bibr"><offsets xml_i="9727" xml_f="9729" txt_i="4228" txt_f="4230">15</offsets></xref><offsets xml_i="9736" xml_f="9893" txt_i="4230" txt_f="4387">]. Spanish dry-cured ham particularly, provides a valuable source of active biopeptides that have been tested in vitro and in animal models of hypertension [</offsets><xref rid="B16-nutrients-09-00321" ref-type="bibr"><offsets xml_i="9944" xml_f="9946" txt_i="4387" txt_f="4389">16</offsets></xref><offsets xml_i="9953" xml_f="9954" txt_i="4389" txt_f="4390">,</offsets><xref rid="B17-nutrients-09-00321" ref-type="bibr"><offsets xml_i="10005" xml_f="10007" txt_i="4390" txt_f="4392">17</offsets></xref><offsets xml_i="10014" xml_f="10162" txt_i="4392" txt_f="4540">]. Besides, the results of a number of studies suggest that dry-cured hams may be healthy and could be included as a regular component of the diet [</offsets><xref rid="B18-nutrients-09-00321" ref-type="bibr"><offsets xml_i="10213" xml_f="10215" txt_i="4540" txt_f="4542">18</offsets></xref><offsets xml_i="10222" xml_f="10385" txt_i="4542" txt_f="4705">]. However, any assessment of biological activity has almost exclusively been limited to assays to detect the inhibition of angiotensin I-converting enzyme (ACE) [</offsets><xref rid="B17-nutrients-09-00321" ref-type="bibr"><offsets xml_i="10436" xml_f="10438" txt_i="4705" txt_f="4707">17</offsets></xref><offsets xml_i="10445" xml_f="11059" txt_i="4707" txt_f="5321">] and few human or mechanistic studies have been designed to explore the wider range of activities of such biopeptides in the CV system. Therefore, the current study aims to establish cause–effect relationships between the consumption of dry-cured ham containing bioactive peptides and any physiological effects observed in individuals with pre-hypertension, looking for cellular changes related to the CV pathophysiology other than just clinical parameters. In this study, we focus on changes in monocytes and platelets as they are involved in inflammatory responses and the regulation of the thrombogenic status.</offsets></p></sec><sec id="sec2-nutrients-09-00321"><title><offsets xml_i="11110" xml_f="11133" txt_i="5323" txt_f="5346">2. Material and Methods</offsets></title><sec id="sec2dot1-nutrients-09-00321"><title><offsets xml_i="11186" xml_f="11207" txt_i="5347" txt_f="5368">2.1. Ethics Statement</offsets></title><p><offsets xml_i="11218" xml_f="11509" txt_i="5369" txt_f="5660">The clinical study was registered in the Clinical Trials Database (ID: NCT02585089), performed in accordance with the Helsinki Declaration and approved by the Ethics Committee of the Catholic University of Murcia (UCAM, April 2015). All enrolled volunteers provided written informed consent.</offsets></p></sec><sec id="sec2dot2-nutrients-09-00321"><title><offsets xml_i="11564" xml_f="11594" txt_i="5662" txt_f="5692">2.2. Study Design and Subjects</offsets></title><p><offsets xml_i="11605" xml_f="12418" txt_i="5693" txt_f="6503">In the context of the 7FP EU Beneficial Effects of Bioactive Compounds in Humans (BACCHUS) project, a two-arm cross-over randomized control trial was assessed at the UCAM, between September 2015 and January 2016. Participants received 80 g/day dry-cured pork ham of &gt;11 months proteolysis (interventional product) and 100 g/day cooked ham (control product) each for 4 weeks. After a two-week washout, the groups exchanged roles for another 4 weeks. The study arms were similar for age, gender, ethnicity, body mass index and BP, which allowed comparisons to be made between them. Thirty-eight apparently healthy Caucasian men and women from the University staff, aged 40–55 years, in good general health and with pre-hypertension were recruited (systolic and diastolic BPs above 125 and 80 mmHg, respectively).</offsets></p><p><offsets xml_i="12425" xml_f="12458" txt_i="6504" txt_f="6537">Exclusion criteria were smokers, </offsets><italic><offsets xml_i="12466" xml_f="12483" txt_i="6537" txt_f="6554">Diabetes mellitus</offsets></italic><offsets xml_i="12492" xml_f="13016" txt_i="6554" txt_f="7078">, diagnosed and treated hypertension, history of cardiovascular events (stroke, myocardial infarction or peripheral vascular disease), cancer and inflammatory diseases. Volunteers whose medications included anti-hypertensives, antiaggregants, anticoagulants, antidepressants, anti-cholinergic or anti-spasmodic agents, the regular use of medication affecting intestinal motility, vasodilators, lipid lowering therapies or fish oil supplements (all other supplements were assessed on a case by case basis) were also excluded.</offsets></p><p><offsets xml_i="13023" xml_f="13557" txt_i="7079" txt_f="7613">A list of restricted foods was given at the beginning of the study in order to avoid the excessive consumption of salt and other cured meat products. Volunteers were asked not to change their dietary patterns and lifestyle during the study. The individuals did not know about the purpose of the study or which of the hams was supposed to be the interventional product. The volunteers were enrolled by simple randomization by only one investigator and the randomization sequence was concealed until the end of the statistical analysis.</offsets></p></sec><sec id="sec2dot3-nutrients-09-00321"><title><offsets xml_i="13612" xml_f="13630" txt_i="7615" txt_f="7633">2.3. Meat Products</offsets></title><p><offsets xml_i="13641" xml_f="13815" txt_i="7634" txt_f="7805">Spanish dry-cured ham with a controlled salt content after &gt;11 months dry-curing process/proteolysis was the interventional product and cooked ham was the control product.</offsets></p><p><offsets xml_i="13822" xml_f="14267" txt_i="7806" txt_f="8248">The Spanish dry-cured ham after an &gt;11 month dry-curing process contained 25% less salt than similar products on the market (4.38% vs. approx. 5.5%). As regard the cooked ham, it contained 2.61% salt, which was lower than the 3.6 g salt per 80 g intake of dry-cured ham. In order to counteract the humidity and salt, a higher amount of cooked ham (control) was given (100 g/day). Hams were manufactured and supplied by the local meat Company </offsets><italic><offsets xml_i="14275" xml_f="14294" txt_i="8248" txt_f="8267">ElPozo Alimentación</offsets></italic><offsets xml_i="14303" xml_f="14787" txt_i="8267" txt_f="8751"> (Alhama de Murcia, Spain) especially for the present clinical study in daily vacuum bags and labelled with safety information (best by date, nutritional composition and storage information). The presence/absence of active biopeptides in the meat products were tested and sequenced using one-dimensional reversed-phase liquid chromatography combined with nano-liquid chromatography and an electrospray ionization source coupled to a quadrupole time-of-flight mass spectrometer at the </offsets><italic><offsets xml_i="14795" xml_f="14845" txt_i="8751" txt_f="8801">Instituto de Agroquímica y Tecnología de Alimentos</offsets></italic><offsets xml_i="14854" xml_f="14873" txt_i="8801" txt_f="8820"> (CSIC, Valencia) [</offsets><xref rid="B19-nutrients-09-00321" ref-type="bibr"><offsets xml_i="14924" xml_f="14926" txt_i="8820" txt_f="8822">19</offsets></xref><offsets xml_i="14933" xml_f="14936" txt_i="8822" txt_f="8825">] (</offsets><xref ref-type="table" rid="nutrients-09-00321-t001"><offsets xml_i="14989" xml_f="14996" txt_i="8825" txt_f="8832">Table 1</offsets></xref><offsets xml_i="15003" xml_f="15005" txt_i="8832" txt_f="8834">).</offsets></p></sec><sec id="sec2dot4-nutrients-09-00321"><title><offsets xml_i="15060" xml_f="15110" txt_i="8836" txt_f="8886">2.4. Blood Sampling and Biochemical Determinations</offsets></title><p><offsets xml_i="15121" xml_f="15375" txt_i="8887" txt_f="9141">For laboratory analysis, 8 h fasting peripheral venous blood samples were collected at four time-points from all participants before and after each period (interventional/control product). Venous blood was collected in EDTA and citrate (0.15%) Vacutainer</offsets><sup><offsets xml_i="15380" xml_f="15381" txt_i="9141" txt_f="9142">®</offsets></sup><offsets xml_i="15387" xml_f="15560" txt_i="9142" txt_f="9315"> tubes. Blood was centrifuged at 3500 rpm for 15 min at room temperature to obtain platelet-poor plasma. Plasma aliquots were stored at −70 °C to allow ELISA batch analysis.</offsets></p></sec><sec id="sec2dot5-nutrients-09-00321"><title><offsets xml_i="15615" xml_f="15634" txt_i="9317" txt_f="9336">2.5. Flow Cytometry</offsets></title><p><offsets xml_i="15645" xml_f="15692" txt_i="9337" txt_f="9384">(a) In vitro assessment of platelet activation:</offsets></p><p><offsets xml_i="15699" xml_f="15973" txt_i="9385" txt_f="9659">Freshly collected citrated blood (450 μL) was incubated with 0.02 mmol/L ADP (adenosine diphosphate) for 2 min. Surface expression of membrane constitutive CD42a (GP IX) and platelet activation markers (P-selectin and PAC-1 binding) were then assessed as already published [</offsets><xref rid="B20-nutrients-09-00321" ref-type="bibr"><offsets xml_i="16024" xml_f="16026" txt_i="9659" txt_f="9661">20</offsets></xref><offsets xml_i="16033" xml_f="16462" txt_i="9661" txt_f="10090">]. After incubation, blood (5 μL) was labelled with 0.05 μg anti-CD42a-PerCP (clone Beb1), anti-CD62P-APC (clone AK-4), PAC-1-FITC (clone PAC-1) (which recognizes the conformationally activated GPIIβ/IIIα) (all from BD Biosciences, Oxford, UK) for 15 min, diluted with 1 mL filtered PBS and then analyzed in a FACS Canto II flow cytometer (Becton Dickinson, Oxford, UK). Twenty thousand platelets were counted in each sample run.</offsets></p><p><offsets xml_i="16469" xml_f="16516" txt_i="10091" txt_f="10138">(b) In vitro assessment of monocyte activation:</offsets></p><p><offsets xml_i="16523" xml_f="17212" txt_i="10139" txt_f="10820">Mouse anti-human monoclonal fluorochrome-conjugated antibodies against CD16-Alexa Fluor 488 (clone DJ130c, AbDSerotec, Oxford, UK), CD14-PerCP (clone MфP9, BD Biosciences, Oxford, UK) were mixed in different tubes with 100 μL freshly collected EDTA blood. The above antibodies were mixed with PE-conjugated antibodies against Toll-like receptor-4 (TLR4), intercellular cell adhesion molecule-1 receptor (ICAM-1R) and CXCR4 (all from R&amp;D Systems); APC-conjugated antibodies against interleukin-6 receptor (IL6R), vascular cell adhesion molecule-1 receptor (VCAM-1R) and CD163 (all from R&amp;D Systems). After incubation for 15 min, red blood cells were lysed by 2 mL of lysing solution</offsets><sup><offsets xml_i="17217" xml_f="17218" txt_i="10820" txt_f="10821">®</offsets></sup><offsets xml_i="17224" xml_f="17606" txt_i="10821" txt_f="11203"> (BD Biosciences) for 15 min, diluted with PBS and immediately analyzed by flow cytometry. Expression of the surface markers was quantified as mean fluorescence intensity (MFI) on different monocyte subsets (CD14++CD16− (Mon1), CD14++CD16+ (Mon2), and CD14+CD16++ (Mon3)). The gating strategy excluded neutrophils, eosinophils, lymphocytes and other granulocytes from the analysis (</offsets><xref ref-type="fig" rid="nutrients-09-00321-f001"><offsets xml_i="17657" xml_f="17665" txt_i="11203" txt_f="11211">Figure 1</offsets></xref><offsets xml_i="17672" xml_f="17792" txt_i="11211" txt_f="11331">). The method was assessed in a BD FACS Canto II flow cytometer (Becton Dickinson, Oxford, UK) as previously described [</offsets><xref rid="B21-nutrients-09-00321" ref-type="bibr"><offsets xml_i="17843" xml_f="17845" txt_i="11331" txt_f="11333">21</offsets></xref><offsets xml_i="17852" xml_f="17895" txt_i="11333" txt_f="11376">], acquiring 120.000 monocytes per sample. </offsets></p></sec><sec id="sec2dot6-nutrients-09-00321"><title><offsets xml_i="17950" xml_f="17969" txt_i="11378" txt_f="11397">2.6. Plasma Markers</offsets></title><p><offsets xml_i="17980" xml_f="18268" txt_i="11398" txt_f="11686">Plasma samples (citrated and EDTA) were used to quantify the levels of soluble platelet and monocyte adhesion markers (P-selectin and VCAM-1, respectively), high sensitive interleukin-6 (hs-IL-6) and monocyte chemoattractant protein 1 (MCP-1) by enzyme-linked immunosorbent assay (ELISA).</offsets></p><p><offsets xml_i="18275" xml_f="18731" txt_i="11687" txt_f="12143">All measurements were performed using recognized high quality human Affymetrix kits (eBioscience, Carlsbad, CA 92008, USA): VCAM-1 antigen (Cat. No. BMS232), hs-IL6 antigen (Cat. No. BMS213HS), P-selectin antigen (Cat. No. BMS219/4) and MCP-1 antigen (Cat. No. 88739922), according to the manufacturer’s recommendations. The lower limits of detection of hs-IL-6, P-selectin, VCAM-1 and MCP-1 were 0.03 pg/mL, 0.2 ng/mL, 0.6 ng/mL and 7 pg/mL, respectively.</offsets></p></sec><sec id="sec2dot7-nutrients-09-00321"><title><offsets xml_i="18786" xml_f="18811" txt_i="12145" txt_f="12170">2.7. Statistical Analyses</offsets></title><p><offsets xml_i="18822" xml_f="19423" txt_i="12171" txt_f="12772">Categorical variables are expressed as frequency (percentage) of volunteers. Continuous markers are expressed as mean ± standard deviation (SD). Extremely skewed variables were Log transformed. For each continuous marker, a regression of values after meat product consumption adjusted for values before consumption was performed. By centering both variables on the mean before consumption, the intercept of the model estimates the average change after consumption. The relative mean change (mean change/mean before –1) was calculated in order to plot variables with different scales on the same graph.</offsets></p><p><offsets xml_i="19430" xml_f="19965" txt_i="12773" txt_f="13308">To estimate the differences of average changes between control and intervention groups, a binary variable (control = 0, intervention = 1) was included in the model. Another binary variable was included to adjust for the potential period effect. Furthermore, a random effect term by individual was used to account for the repeated measures. We checked the model assumptions on the residuals with plots and normality tests. R 3.3.1 software was used for the statistical analyses (R Foundation for Statistical Computing, Vienna, Austria).</offsets></p></sec></sec><sec id="sec3-nutrients-09-00321"><title><offsets xml_i="20022" xml_f="20032" txt_i="13311" txt_f="13321">3. Results</offsets></title><p><offsets xml_i="20043" xml_f="20136" txt_i="13322" txt_f="13415">Clinical characteristics, including demography and BP, of the study population, are shown in </offsets><xref ref-type="table" rid="nutrients-09-00321-t002"><offsets xml_i="20189" xml_f="20196" txt_i="13415" txt_f="13422">Table 2</offsets></xref><offsets xml_i="20203" xml_f="20395" txt_i="13422" txt_f="13614">. Thirty-eight subjects (44.3 ± 5.3 years old; 82% males) were included in the study. Readings of systolic BP were above 125 mmHg, considered as normal-high blood pressure or pre-hypertension.</offsets></p><p><offsets xml_i="20402" xml_f="20539" txt_i="13615" txt_f="13752">The baseline parameters of the participants were compared to data obtained after 4 weeks of consuming dry-cured pork ham and cooked ham (</offsets><xref ref-type="table" rid="nutrients-09-00321-t003"><offsets xml_i="20592" xml_f="20599" txt_i="13752" txt_f="13759">Table 3</offsets></xref><offsets xml_i="20606" xml_f="20717" txt_i="13759" txt_f="13870">). Body mass index and fat content were not affected by the interventional product nor by the control product (</offsets><italic><offsets xml_i="20725" xml_f="20726" txt_i="13870" txt_f="13871">p</offsets></italic><offsets xml_i="20735" xml_f="20763" txt_i="13871" txt_f="13896"> &gt; 0.05, data not shown).</offsets></p><sec id="sec3dot1-nutrients-09-00321"><title><offsets xml_i="20812" xml_f="20834" txt_i="13897" txt_f="13919">3.1. Plasmatic Markers</offsets></title><p><offsets xml_i="20845" xml_f="20943" txt_i="13920" txt_f="14018">A comparison between plasma biochemical markers before and after dry-cured ham intake is shown in </offsets><xref ref-type="table" rid="nutrients-09-00321-t003"><offsets xml_i="20996" xml_f="21003" txt_i="14018" txt_f="14025">Table 3</offsets></xref><offsets xml_i="21010" xml_f="21015" txt_i="14025" txt_f="14030"> and </offsets><xref ref-type="fig" rid="nutrients-09-00321-f002"><offsets xml_i="21066" xml_f="21074" txt_i="14030" txt_f="14038">Figure 2</offsets></xref><offsets xml_i="21081" xml_f="21264" txt_i="14038" txt_f="14221">. After 4 weeks of regular dry-cured ham intake and adjusting for a potential period effect, soluble P-selectin (sCD62P) concentration was markedly lower than in baseline conditions (</offsets><italic><offsets xml_i="21272" xml_f="21273" txt_i="14221" txt_f="14222">p</offsets></italic><offsets xml_i="21282" xml_f="21416" txt_i="14222" txt_f="14356"> = 0.0035). The mean difference of soluble P-selectin levels was still slightly decreased between interventional and control periods (</offsets><italic><offsets xml_i="21424" xml_f="21425" txt_i="14356" txt_f="14357">p</offsets></italic><offsets xml_i="21434" xml_f="21620" txt_i="14357" txt_f="14543"> = 0.0625). Besides, MCP-1 levels were found unaltered after the interventional period, but when the cooked ham intake was included, a significant increase in MCP-1 levels was observed (</offsets><italic><offsets xml_i="21628" xml_f="21629" txt_i="14543" txt_f="14544">p</offsets></italic><offsets xml_i="21638" xml_f="21775" txt_i="14544" txt_f="14681"> = 0.0234). Decreased concentrations of the soluble inflammatory mediator (IL6) were measured in plasma after the interventional period (</offsets><italic><offsets xml_i="21783" xml_f="21784" txt_i="14681" txt_f="14682">p</offsets></italic><offsets xml_i="21793" xml_f="21887" txt_i="14682" txt_f="14776"> = 0.037). Such an effect was still shown after adjusting with the control cooked ham period (</offsets><italic><offsets xml_i="21895" xml_f="21896" txt_i="14776" txt_f="14777">p</offsets></italic><offsets xml_i="21905" xml_f="22052" txt_i="14777" txt_f="14924"> = 0.049). In contrast, there were no significant differences in plasma concentrations of soluble VCAM-1 after dry-cured ham nor cooked ham intake.</offsets></p></sec><sec id="sec3dot2-nutrients-09-00321"><title><offsets xml_i="22107" xml_f="22141" txt_i="14926" txt_f="14960">3.2. Effect on Platelet Activation</offsets></title><p><offsets xml_i="22152" xml_f="22325" txt_i="14961" txt_f="15134">The regular consumption of bioactive peptides resulted in a significant decrease in P-selectin (CD62P) expression by 11.17% (55.24 points) in platelets stimulated with ADP (</offsets><italic><offsets xml_i="22333" xml_f="22334" txt_i="15134" txt_f="15135">p</offsets></italic><offsets xml_i="22343" xml_f="22358" txt_i="15135" txt_f="15150"> = 0.0000272) (</offsets><xref ref-type="table" rid="nutrients-09-00321-t004"><offsets xml_i="22411" xml_f="22418" txt_i="15150" txt_f="15157">Table 4</offsets></xref><offsets xml_i="22425" xml_f="22430" txt_i="15157" txt_f="15162"> and </offsets><xref ref-type="fig" rid="nutrients-09-00321-f003"><offsets xml_i="22481" xml_f="22489" txt_i="15162" txt_f="15170">Figure 3</offsets></xref><offsets xml_i="22496" xml_f="22640" txt_i="15170" txt_f="15314">). However, changes in the glycoprotein IIb/IIIα expression (PAC-1 monoclonal antibody binding) did not change after the 30 days’ intervention (</offsets><italic><offsets xml_i="22648" xml_f="22649" txt_i="15314" txt_f="15315">p</offsets></italic><offsets xml_i="22658" xml_f="22668" txt_i="15315" txt_f="15325"> = 0.447).</offsets></p></sec><sec id="sec3dot3-nutrients-09-00321"><title><offsets xml_i="22723" xml_f="22755" txt_i="15327" txt_f="15359">3.3. Effect on Monocytes Markers</offsets></title><p><offsets xml_i="22766" xml_f="22957" txt_i="15360" txt_f="15551">There was no difference in the expression of surface ICAM-1 receptor between the two time points in the different subtypes of monocytes. Similar data were also obtained for CD163 expression (</offsets><xref ref-type="table" rid="nutrients-09-00321-t004"><offsets xml_i="23010" xml_f="23017" txt_i="15551" txt_f="15558">Table 4</offsets></xref><offsets xml_i="23024" xml_f="23096" txt_i="15558" txt_f="15630">). However, expression of CD163 in Mon3 decreased significantly by 39% (</offsets><italic><offsets xml_i="23104" xml_f="23105" txt_i="15630" txt_f="15631">p</offsets></italic><offsets xml_i="23114" xml_f="23129" txt_i="15631" txt_f="15646"> = 0.0000024) (</offsets><xref ref-type="fig" rid="nutrients-09-00321-f003"><offsets xml_i="23180" xml_f="23188" txt_i="15646" txt_f="15654">Figure 3</offsets></xref><offsets xml_i="23195" xml_f="23197" txt_i="15654" txt_f="15656">).</offsets></p><p><offsets xml_i="23204" xml_f="23349" txt_i="15657" txt_f="15802">Besides, the expression levels of VCAM-1 receptor and CXCR4 were significantly higher for all three subsets compared to baseline conditions (all </offsets><italic><offsets xml_i="23357" xml_f="23358" txt_i="15802" txt_f="15803">p</offsets></italic><offsets xml_i="23367" xml_f="23468" txt_i="15803" txt_f="15901"> &lt; 0.02). Dry-cured ham intake produced an important increase of 343% in VCAM-1R levels in Mon 2 (</offsets><italic><offsets xml_i="23476" xml_f="23477" txt_i="15901" txt_f="15902">p</offsets></italic><offsets xml_i="23486" xml_f="23499" txt_i="15902" txt_f="15915"> = 0.00075) (</offsets><xref ref-type="fig" rid="nutrients-09-00321-f003"><offsets xml_i="23550" xml_f="23558" txt_i="15915" txt_f="15923">Figure 3</offsets></xref><offsets xml_i="23565" xml_f="23681" txt_i="15923" txt_f="16039">). Expression levels of TLR4 in the three monocytes subsets were also strongly affected after the intervention (all </offsets><italic><offsets xml_i="23689" xml_f="23690" txt_i="16039" txt_f="16040">p</offsets></italic><offsets xml_i="23699" xml_f="23712" txt_i="16040" txt_f="16050"> &lt; 0.05) (</offsets><xref ref-type="fig" rid="nutrients-09-00321-f003"><offsets xml_i="23763" xml_f="23771" txt_i="16050" txt_f="16058">Figure 3</offsets></xref><offsets xml_i="23778" xml_f="23843" txt_i="16058" txt_f="16123">). Similarly, IL6R expression was down-regulated by 39% in Mon3 (</offsets><italic><offsets xml_i="23851" xml_f="23852" txt_i="16123" txt_f="16124">p</offsets></italic><offsets xml_i="23861" xml_f="23987" txt_i="16124" txt_f="16250"> = 0.0000632) but these differences did not reach statistical significance for the other two monocyte subsets, Mon1 and Mon2 (</offsets><xref ref-type="table" rid="nutrients-09-00321-t004"><offsets xml_i="24040" xml_f="24047" txt_i="16250" txt_f="16257">Table 4</offsets></xref><offsets xml_i="24054" xml_f="24094" txt_i="16257" txt_f="16297">), although a trend was found for Mon2 (</offsets><italic><offsets xml_i="24102" xml_f="24103" txt_i="16297" txt_f="16298">p</offsets></italic><offsets xml_i="24112" xml_f="24123" txt_i="16298" txt_f="16309"> = 0.0568).</offsets></p></sec></sec><sec id="sec4-nutrients-09-00321"><title><offsets xml_i="24180" xml_f="24193" txt_i="16312" txt_f="16325">4. Discussion</offsets></title><p><offsets xml_i="24204" xml_f="24442" txt_i="16326" txt_f="16564">Dietary bioactives are compounds of food origin that safely deliver health benefits, although their mechanisms of action are usually poorly understood. Generally, meat and meat products are not ordinarily associated with health benefits [</offsets><xref rid="B22-nutrients-09-00321" ref-type="bibr"><offsets xml_i="24493" xml_f="24495" txt_i="16564" txt_f="16566">22</offsets></xref><offsets xml_i="24502" xml_f="25128" txt_i="16566" txt_f="17192">]. However, in vitro tested health-promoting bioactive peptides are naturally generated from meat proteins during curing or fermentation. Moreover, it is a challenge for the food industry to identify the functionality of bioactives, in order to make products healthier and, possibly to claim that they may be regarded as functional foods. Therefore, the aim of this investigation was to evaluate the effect of the regular consumption of dry-cured pork ham containing characterized active biopeptides among other possible bioactives on platelet activation, monocytes phenotype and plasma markers of inflammation and activation.</offsets></p><p><offsets xml_i="25135" xml_f="25275" txt_i="17193" txt_f="17333">The presence of naturally active biopeptides in the meat product was confirmed by a peptidomic strategy using mass spectrometry techniques [</offsets><xref rid="B19-nutrients-09-00321" ref-type="bibr"><offsets xml_i="25326" xml_f="25328" txt_i="17333" txt_f="17335">19</offsets></xref><offsets xml_i="25335" xml_f="25668" txt_i="17335" txt_f="17668">]. Cooked ham was chosen as the control product because active biopeptides are not released during its manufacture, as confirmed here. To our knowledge, no previous study has associated the regular consumption of meat peptides with in vivo cellular changes, even though several in vitro studies suggested possible action mechanisms [</offsets><xref rid="B17-nutrients-09-00321" ref-type="bibr"><offsets xml_i="25719" xml_f="25721" txt_i="17668" txt_f="17670">17</offsets></xref><offsets xml_i="25728" xml_f="25729" txt_i="17670" txt_f="17671">,</offsets><xref rid="B23-nutrients-09-00321" ref-type="bibr"><offsets xml_i="25780" xml_f="25782" txt_i="17671" txt_f="17673">23</offsets></xref><offsets xml_i="25789" xml_f="25790" txt_i="17673" txt_f="17674">,</offsets><xref rid="B24-nutrients-09-00321" ref-type="bibr"><offsets xml_i="25841" xml_f="25843" txt_i="17674" txt_f="17676">24</offsets></xref><offsets xml_i="25850" xml_f="25852" txt_i="17676" txt_f="17678">].</offsets></p><p><offsets xml_i="25859" xml_f="26146" txt_i="17679" txt_f="17966">Impaired platelet function results in a higher degree of degranulation and translocation of P-selectin (CD62P) to the outer plasmatic membrane, both of which have been related to CV pathological conditions such as hypertension, diabetes, myocardial infarction, heart failure and stroke [</offsets><xref rid="B25-nutrients-09-00321" ref-type="bibr"><offsets xml_i="26197" xml_f="26199" txt_i="17966" txt_f="17968">25</offsets></xref><offsets xml_i="26206" xml_f="26307" txt_i="17968" txt_f="18069">]. Accordingly, P-selectin has also been proposed as a novel therapeutic target in vascular disease [</offsets><xref rid="B26-nutrients-09-00321" ref-type="bibr"><offsets xml_i="26358" xml_f="26360" txt_i="18069" txt_f="18071">26</offsets></xref><offsets xml_i="26367" xml_f="26959" txt_i="18071" txt_f="18663">]. One of the more significant findings to emerge from this study is that the intake of dry-cured ham enriched in active biopeptides is related to a decrease in the platelet expression of this activation marker, P-selectin. Moreover, the findings also point to a reduction of soluble P-selectin after the interventional period, even adjusting with the cooked ham intake. This data also supports a role for active biopeptides in modulating in vivo platelet function. The ability to inhibit platelet function has previously been confirmed ex vivo in the presence of other vegetable bioactives [</offsets><xref rid="B27-nutrients-09-00321" ref-type="bibr"><offsets xml_i="27010" xml_f="27012" txt_i="18663" txt_f="18665">27</offsets></xref><offsets xml_i="27019" xml_f="27370" txt_i="18665" txt_f="19016">]. Nonetheless, it is unclear why this occurs or what role this response might play in pathological conditions, other than in healthy individuals with normal-high non-treated hypertension. Thereby, the current study opens up an interesting avenue for further research into the mechanism(s) of these dietary peptides in platelet phenotype and function.</offsets></p><p><offsets xml_i="27377" xml_f="28116" txt_i="19017" txt_f="19756">The roles of monocytes in CVD are diverse, including their involvement in inflammatory responses and the regulation of the thrombogenic status. In experimental hypertension, monocytes increase their adhesion to the endothelium integrins (ICAM-1, VCAM-1) through their receptors (ICAM-1R and VCAM-1R). Moreover, monocytes have also been implicated in physiologically beneficial processes related to the scavenging of pathological material, angiogenesis and repair through stromal derived factor-1 (SDF1) binding to CXCR4. The diversity of monocytes functions can be partly attributed to the existence of different monocytes subsets (Mon1, Mon2 and Mon3) that can be distinguished according to specific phenotypic and functional properties [</offsets><xref rid="B28-nutrients-09-00321" ref-type="bibr"><offsets xml_i="28167" xml_f="28169" txt_i="19756" txt_f="19758">28</offsets></xref><offsets xml_i="28176" xml_f="28667" txt_i="19758" txt_f="20249">]. In this line, the second major finding of the current study was that the consumption of dry-cured ham impaired the basal expression of several markers in circulating monocytes. For instance, the expression of the integrin α4 receptor (VCAM-1R) and CXCR4 (SDF1 receptor) increased significantly in the three subtypes of monocytes. Recent investigations found that VCAM-1R and CXCR4 in monocytes were higher in healthy volunteers compared to individuals with coronary artery disease (CAD) [</offsets><xref rid="B21-nutrients-09-00321" ref-type="bibr"><offsets xml_i="28718" xml_f="28720" txt_i="20249" txt_f="20251">21</offsets></xref><offsets xml_i="28727" xml_f="28928" txt_i="20251" txt_f="20452">], confirming an improvement of the physiological status after the long-term consumption of dry-cured ham. CD163 and TLR4 are proteins involved in immunity, scavenging and the recognition of antigens [</offsets><xref rid="B29-nutrients-09-00321" ref-type="bibr"><offsets xml_i="28979" xml_f="28981" txt_i="20452" txt_f="20454">29</offsets></xref><offsets xml_i="28988" xml_f="29434" txt_i="20454" txt_f="20900">]. The TLR4 expression also increased after the intervention in all the three monocyte subsets. The expression of CD163 was higher after the intervention in the minority Mon3. Concerning the expression of IL6R, levels remained unaltered after the intervention in the main subset Mon1 but it significantly decreased in Mon3 and a trend was shown for Mon2, once more in agreement with previous results with healthy volunteers towards CAD patients [</offsets><xref rid="B21-nutrients-09-00321" ref-type="bibr"><offsets xml_i="29485" xml_f="29487" txt_i="20900" txt_f="20902">21</offsets></xref><offsets xml_i="29494" xml_f="30073" txt_i="20902" txt_f="21481">]. Whether IL6R levels decrease as a consequence of lower transcription cannot be formally demonstrated here. Nonetheless, greater IL6 binding to IL6R might not be the case because the plasmatic levels of IL6 were substantially lower after the regular consumption of cured meat adjusted with a potential period effect. Neither can the effects be attributed to observer bias or lifestyle confounders. In relation to that, the current analysis also identified increased plasmatic MCP-1 levels, which regulate the migration of monocytes, between the intervention and control groups.</offsets></p><p><offsets xml_i="30080" xml_f="30215" txt_i="21482" txt_f="21617">Taken together, those observations seem to suggest intake-dependent changes in monocytes and an improvement in the inflammatory status.</offsets></p><sec><title><offsets xml_i="30231" xml_f="30242" txt_i="21618" txt_f="21629">Limitations</offsets></title><p><offsets xml_i="30253" xml_f="31251" txt_i="21630" txt_f="22628">Differences in the molecular parameters were only shown after the interventional period of time. However, plasmatic markers were analyzed after the intake of both meat products, allowing a valid estimate of the dry-cured ham intake effect. Although irrelevant from the clinical point of view, it is important to mention that volunteers took lower salt amounts during cooked ham intake (1 g/day less), compared to the interventional period. The effect of dry-cured ham consumption on platelet and monocytes phenotype cannot be directly attributed to active biopeptides; nonetheless, it is important to underline the broad range of sequenced peptides contained in the dry-cured ham and absent in the control product. The ideal quantity of biopeptides from any origin that would provide beneficial effects in humans has not been determined; neither has the amount of biopeptides contained in the ham. Nevertheless, the study was designed to involve the highest feasible daily intake of dry-cured meat.</offsets></p></sec></sec><sec id="sec5-nutrients-09-00321"><title><offsets xml_i="31308" xml_f="31322" txt_i="22631" txt_f="22645">5. Conclusions</offsets></title><p><offsets xml_i="31333" xml_f="32135" txt_i="22646" txt_f="23448">As the era of molecular nutrition unfolds, a greater understanding of how these foods and their components influence cellular mechanisms will surely arise. Current molecular approaches, such as flow cytometry, can aid the scientific community in gaining a deeper understanding related to the effects of active compounds over a variety of cell types, tissues and pathological conditions. Such information will be critical in the development of healthier products for reducing the CV burden. In particular, the present results lead to the conclusion that active biopeptides have potential therapeutic effects in the vascular system, and help identify future molecular targets for the prevention of CV risk factors in healthy individuals. In addition, whether these new categories of active compounds affe</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>The authors are grateful to <italic>El Pozo Alimentación</italic> (Murcia, Spain) for the ham product. The IATA (Instituto de Agroquímica y Tecnología de Alimentos, CSIC Valencia) characterized the meat products. We also acknowledge the Servicio de Inmunología, Hospital Clínico Universitario Virgen de la Arrixaca for allowing use of the flow cytometer. The research reported in this article was supported by the Project BACCHUS (FP7-KBBE-2012-6-single stage, European Commission Grant Agreement 312090). S.M.G. was supported by the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007-2013) under REA grant agreement No. 608765. S.M.S. belongs to the “<italic>Programa de Doctorado en Ciencias de la Salud. Universidad Católica de Murcia</italic> (UCAM)” and holds a FPU grant (FPU 15/03134) from the Ministry of Education (Spain).</p></ack><notes><title>Author Contributions</title><p>S.M.M.-S. recruited and performed the cytometric approach. A.M. optimized the flow cytometer protocol. D.P.-M. performed the regression models. M.P.Z.-R. and J.A.-A. designed the study. S.M.-G. drafted the manuscript and controlled the recruitment.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>All authors declare no conflict of interests.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ACE</td><td align="left" valign="middle" rowspan="1" colspan="1">Angiotensin I Converting Enzyme</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ADP</td><td align="left" valign="middle" rowspan="1" colspan="1">Adenosine diphosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BMI</td><td align="left" valign="middle" rowspan="1" colspan="1">Body Mass Index</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BP</td><td align="left" valign="middle" rowspan="1" colspan="1">Blood Pressure</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CAD</td><td align="left" valign="middle" rowspan="1" colspan="1">Coronary artery Disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CVD</td><td align="left" valign="middle" rowspan="1" colspan="1">Cardiovascular Disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FSC/SSC</td><td align="left" valign="middle" rowspan="1" colspan="1">Forward-scattered light/Side-scattered light</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">hsIL6</td><td align="left" valign="middle" rowspan="1" colspan="1">high-sensitivity Interleukin 6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICAM-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Intercellular Adhesion Molecule-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MCP-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Monocyte Chemoattractant Protein-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MIF</td><td align="left" valign="middle" rowspan="1" colspan="1">Mean Fluorescence Intensity</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mon</td><td align="left" valign="middle" rowspan="1" colspan="1">Monocyte</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SDF1</td><td align="left" valign="middle" rowspan="1" colspan="1">Stromal Derived Factor-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TLR4</td><td align="left" valign="middle" rowspan="1" colspan="1">Toll-Like Receptor 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VCAM-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Vascular Cell Adhesion Molecule 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">UCAM</td><td align="left" valign="middle" rowspan="1" colspan="1">Catholic University of Murcia</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-nutrients-09-00321"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eussen</surname><given-names>S.R.</given-names></name><name><surname>Verhagen</surname><given-names>H.</given-names></name><name><surname>Klungel</surname><given-names>O.H.</given-names></name><name><surname>Garssen</surname><given-names>J.</given-names></name><name><surname>van Loveren</surname><given-names>H.</given-names></name><name><surname>van Kranen</surname><given-names>H.J.</given-names></name><name><surname>Rompelberg</surname><given-names>C.J.</given-names></name></person-group><article-title>Functional foods and dietary supplements: Products at the interface between pharma and nutrition</article-title><source>Eur. J. Pharmacol.</source><year>2011</year><volume>668</volume><issue>Suppl. S1</issue><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2011.07.008</pub-id><pub-id pub-id-type="pmid">21816140</pub-id></element-citation></ref><ref id="B2-nutrients-09-00321"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aihara</surname><given-names>K.</given-names></name><name><surname>Osaka</surname><given-names>M.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name></person-group><article-title>Oral administration of the milk casein-derived tripeptide Val-Pro-Pro attenuates high-fat diet-induced adipose tissue inflammation in mice</article-title><source>Br. J. Nutr.</source><year>2014</year><volume>112</volume><fpage>513</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1017/S0007114514001147</pub-id><pub-id pub-id-type="pmid">24870967</pub-id></element-citation></ref><ref id="B3-nutrients-09-00321"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjørndal</surname><given-names>B.</given-names></name><name><surname>Berge</surname><given-names>C.</given-names></name><name><surname>Ramsvik</surname><given-names>M.S.</given-names></name><name><surname>Svardal</surname><given-names>A.</given-names></name><name><surname>Bohov</surname><given-names>P.</given-names></name><name><surname>Skorve</surname><given-names>J.</given-names></name><name><surname>Berge</surname><given-names>R.K.</given-names></name></person-group><article-title>A fish protein hydrolysate alters fatty acid composition in liver and adipose tissue and increases plasma carnitine levels in a mouse model of chronic inflammation</article-title><source>Lipids Health Dis.</source><year>2013</year><volume>12</volume><fpage>143</fpage><pub-id pub-id-type="doi">10.1186/1476-511X-12-143</pub-id><pub-id pub-id-type="pmid">24098955</pub-id></element-citation></ref><ref id="B4-nutrients-09-00321"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girgih</surname><given-names>A.T.</given-names></name><name><surname>Alashi</surname><given-names>A.M.</given-names></name><name><surname>He</surname><given-names>R.</given-names></name><name><surname>Malomo</surname><given-names>S.A.</given-names></name><name><surname>Raj</surname><given-names>P.</given-names></name><name><surname>Netticadan</surname><given-names>T.</given-names></name><name><surname>Aluko</surname><given-names>R.E.</given-names></name></person-group><article-title>A novel hemp seed meal protein hydrolysate reduces oxidative stress factors in spontaneously hypertensive rats</article-title><source>Nutrients</source><year>2014</year><volume>6</volume><fpage>5652</fpage><lpage>5266</lpage><pub-id pub-id-type="doi">10.3390/nu6125652</pub-id><pub-id pub-id-type="pmid">25493943</pub-id></element-citation></ref><ref id="B5-nutrients-09-00321"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borissoff</surname><given-names>J.I.</given-names></name><name><surname>Spronk</surname><given-names>H.M.</given-names></name><name><surname>ten Cate</surname><given-names>H.</given-names></name></person-group><article-title>The hemostatic system as a modulator of atherosclerosis</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>364</volume><fpage>1746</fpage><lpage>1760</lpage><pub-id pub-id-type="pmid">21542745</pub-id></element-citation></ref><ref id="B6-nutrients-09-00321"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passacquale</surname><given-names>G.</given-names></name><name><surname>Vamadevan</surname><given-names>P.</given-names></name><name><surname>Pereira</surname><given-names>L.</given-names></name><name><surname>Hamid</surname><given-names>C.</given-names></name><name><surname>Corrigall</surname><given-names>V.</given-names></name><name><surname>Ferro</surname><given-names>A.</given-names></name></person-group><article-title>Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e25595</elocation-id><pub-id pub-id-type="pmid">22022418</pub-id></element-citation></ref><ref id="B7-nutrients-09-00321"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ed Rainger</surname><given-names>G.</given-names></name><name><surname>Chimen</surname><given-names>M.</given-names></name><name><surname>Harrison</surname><given-names>M.J.</given-names></name><name><surname>Yates</surname><given-names>C.M.</given-names></name><name><surname>Harrison</surname><given-names>P.</given-names></name><name><surname>Watson</surname><given-names>S.P.</given-names></name><name><surname>Lordkipanizdé</surname><given-names>M.</given-names></name><name><surname>Nash</surname><given-names>G.B.</given-names></name></person-group><article-title>The role of platelets in the recruitment of leukocytes during vascular disease</article-title><source>Platelets</source><year>2015</year><volume>26</volume><fpage>507</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">26196409</pub-id></element-citation></ref><ref id="B8-nutrients-09-00321"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Ye</surname><given-names>X.</given-names></name><name><surname>Ming</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Su</surname><given-names>X.</given-names></name><name><surname>Kong</surname><given-names>Y.</given-names></name></person-group><article-title>A Novel Direct Factor Xa Inhibitory Peptide with Anti-Platelet Aggregation Activity from Agkistrodon acutus Venom Hydrolysates</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>10846</fpage><pub-id pub-id-type="doi">10.1038/srep10846</pub-id><pub-id pub-id-type="pmid">26035670</pub-id></element-citation></ref><ref id="B9-nutrients-09-00321"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majumder</surname><given-names>K.</given-names></name><name><surname>Chakrabarti</surname><given-names>S.</given-names></name><name><surname>Davidge</surname><given-names>S.T.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name></person-group><article-title>Structure and activity study of egg protein ovotransferrin derived peptides (IRW and IQW) on endothelial inflammatory response and oxidative stress</article-title><source>J. Agric. Food Chem.</source><year>2013</year><volume>61</volume><fpage>2120</fpage><lpage>2129</lpage><pub-id pub-id-type="doi">10.1021/jf3046076</pub-id><pub-id pub-id-type="pmid">23317476</pub-id></element-citation></ref><ref id="B10-nutrients-09-00321"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>L.Q.</given-names></name><name><surname>Xu</surname><given-names>J.Y.</given-names></name><name><surname>Dong</surname><given-names>J.Y.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>van Bladeren</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>Lactotripeptides intake and blood pressure management: A meta-analysis of randomised controlled clinical trials</article-title><source>Nutr. Metab. Cardiovasc. Dis.</source><year>2013</year><volume>23</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2013.02.006</pub-id><pub-id pub-id-type="pmid">23566677</pub-id></element-citation></ref><ref id="B11-nutrients-09-00321"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bähr</surname><given-names>M.</given-names></name><name><surname>Fechner</surname><given-names>A.</given-names></name><name><surname>Kiehntopf</surname><given-names>M.</given-names></name><name><surname>Jahreis</surname><given-names>G.</given-names></name></person-group><article-title>Consuming a mixed diet enriched with lupin protein beneficially affects plasma lipids in hypercholesterolemic subjects: A randomized controlled trial</article-title><source>Clin. Nutr.</source><year>2015</year><volume>34</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2014.03.008</pub-id><pub-id pub-id-type="pmid">24746974</pub-id></element-citation></ref><ref id="B12-nutrients-09-00321"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majumder</surname><given-names>K.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name></person-group><article-title>Molecular targets of antihypertensive peptides: Understanding the mechanisms of action based on the pathophysiology of hypertension</article-title><source>Int. J. Mol. Sci.</source><year>2014</year><volume>16</volume><fpage>256</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.3390/ijms16010256</pub-id><pub-id pub-id-type="pmid">25547491</pub-id></element-citation></ref><ref id="B13-nutrients-09-00321"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>J.T.</given-names></name><name><surname>Ross</surname><given-names>R.P.</given-names></name><name><surname>Bolton</surname><given-names>D.</given-names></name><name><surname>Fitzgerald</surname><given-names>G.F.</given-names></name><name><surname>Stanton</surname><given-names>C.</given-names></name></person-group><article-title>Bioactive peptides from muscle sources: Meat and fish</article-title><source>Nutrients</source><year>2011</year><volume>3</volume><fpage>765</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.3390/nu3090765</pub-id><pub-id pub-id-type="pmid">22254123</pub-id></element-citation></ref><ref id="B14-nutrients-09-00321"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudero</surname><given-names>E.</given-names></name><name><surname>Mora</surname><given-names>L.</given-names></name><name><surname>Fraser</surname><given-names>P.D.</given-names></name><name><surname>Aristoy</surname><given-names>M.C.</given-names></name><name><surname>Arihara</surname><given-names>K.</given-names></name><name><surname>Toldrá</surname><given-names>F.</given-names></name></person-group><article-title>Purification and Identification of antihypertensive peptides in Spanish dry-cured ham</article-title><source>J. Proteom.</source><year>2013</year><volume>78</volume><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1016/j.jprot.2012.10.019</pub-id><pub-id pub-id-type="pmid">23117181</pub-id></element-citation></ref><ref id="B15-nutrients-09-00321"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mora</surname><given-names>L.</given-names></name><name><surname>Gallego</surname><given-names>M.</given-names></name><name><surname>Escudero</surname><given-names>E.</given-names></name><name><surname>Reig</surname><given-names>M.</given-names></name><name><surname>Aristoy</surname><given-names>M.C.</given-names></name><name><surname>Toldrá</surname><given-names>F.</given-names></name></person-group><article-title>Small peptides hydrolysis in dry-cured meats</article-title><source>Int. J. Food Microbiol.</source><year>2015</year><volume>212</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.ijfoodmicro.2015.04.018</pub-id><pub-id pub-id-type="pmid">25944374</pub-id></element-citation></ref><ref id="B16-nutrients-09-00321"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudero</surname><given-names>E.</given-names></name><name><surname>Aristoy</surname><given-names>M.C.</given-names></name><name><surname>Nishimura</surname><given-names>H.</given-names></name><name><surname>Arihara</surname><given-names>K.</given-names></name><name><surname>Toldrá</surname><given-names>F.</given-names></name></person-group><article-title>Antihypertensive effect and antioxidant activity of peptide fractions extracted from Spanish dry-cured ham</article-title><source>Meat Sci.</source><year>2012</year><volume>91</volume><fpage>306</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.meatsci.2012.02.008</pub-id><pub-id pub-id-type="pmid">22405909</pub-id></element-citation></ref><ref id="B17-nutrients-09-00321"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudero</surname><given-names>E.</given-names></name><name><surname>Mora</surname><given-names>L.</given-names></name><name><surname>Toldrá</surname><given-names>F.</given-names></name></person-group><article-title>Stability of ACE inhibitory ham peptides against heat treatment and in vitro digestion</article-title><source>Food Chem.</source><year>2014</year><volume>161</volume><fpage>305</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2014.03.117</pub-id><pub-id pub-id-type="pmid">24837954</pub-id></element-citation></ref><ref id="B18-nutrients-09-00321"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiménez-Colmenero</surname><given-names>F.</given-names></name><name><surname>Ventanas</surname><given-names>J.</given-names></name><name><surname>Toldrá</surname><given-names>F.</given-names></name></person-group><article-title>Nutritional composition of dry-cured ham and its role in a healthy diet</article-title><source>Meat Sci.</source><year>2010</year><volume>84</volume><fpage>585</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1016/j.meatsci.2009.10.029</pub-id><pub-id pub-id-type="pmid">20374828</pub-id></element-citation></ref><ref id="B19-nutrients-09-00321"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallego</surname><given-names>M.</given-names></name><name><surname>Mora</surname><given-names>L.</given-names></name><name><surname>Toldrá</surname><given-names>F.</given-names></name></person-group><article-title>Peptidomics as a tool for quality control in dry-cured ham processing</article-title><source>J. Proteom.</source><year>2016</year><volume>147</volume><fpage>98</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.jprot.2016.02.020</pub-id><pub-id pub-id-type="pmid">26926439</pub-id></element-citation></ref><ref id="B20-nutrients-09-00321"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montoro-Garcia</surname><given-names>S.</given-names></name><name><surname>Shantsila</surname><given-names>E.</given-names></name><name><surname>Hernandez-Romero</surname><given-names>D.</given-names></name><name><surname>Jover</surname><given-names>E.</given-names></name><name><surname>Valdes</surname><given-names>M.</given-names></name><name><surname>Marin</surname><given-names>F.</given-names></name><name><surname>Lip</surname><given-names>G.Y.</given-names></name></person-group><article-title>Small-size platelet microparticles trigger platelet and monocyte functionality and modulate thrombogenesis via P-selectin</article-title><source>Br. J. Haematol.</source><year>2014</year><volume>166</volume><fpage>571</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1111/bjh.12913</pub-id><pub-id pub-id-type="pmid">24766273</pub-id></element-citation></ref><ref id="B21-nutrients-09-00321"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shantsila</surname><given-names>E.</given-names></name><name><surname>Tapp</surname><given-names>L.D.</given-names></name><name><surname>Wrigley</surname><given-names>B.J.</given-names></name><name><surname>Pamukcu</surname><given-names>B.</given-names></name><name><surname>Apostolakis</surname><given-names>S.</given-names></name><name><surname>Montoro-Garcia</surname><given-names>S.</given-names></name><name><surname>Lip</surname><given-names>G.Y.</given-names></name></person-group><article-title>Monocyte subsets in coronary artery disease and their associations with markers of inflammation and fibrinolysis</article-title><source>Atherosclerosis</source><year>2014</year><volume>234</volume><fpage>4</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.02.009</pub-id><pub-id pub-id-type="pmid">24583499</pub-id></element-citation></ref><ref id="B22-nutrients-09-00321"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micha</surname><given-names>R.</given-names></name><name><surname>Michas</surname><given-names>G.</given-names></name><name><surname>Mozaffarian</surname><given-names>D.</given-names></name></person-group><article-title>Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes—An updated review of the evidence</article-title><source>Curr. Atheroscler. Rep.</source><year>2012</year><volume>14</volume><fpage>515</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1007/s11883-012-0282-8</pub-id><pub-id pub-id-type="pmid">23001745</pub-id></element-citation></ref><ref id="B23-nutrients-09-00321"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallego</surname><given-names>M.</given-names></name><name><surname>Aristoy</surname><given-names>M.C.</given-names></name><name><surname>Toldrá</surname><given-names>F.</given-names></name></person-group><article-title>Dipeptidyl peptidase IV inhibitory peptides generated in Spanish dry-cured ham</article-title><source>Meat Sci.</source><year>2014</year><volume>96</volume><fpage>757</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1016/j.meatsci.2013.09.014</pub-id><pub-id pub-id-type="pmid">24200567</pub-id></element-citation></ref><ref id="B24-nutrients-09-00321"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudero</surname><given-names>E.</given-names></name><name><surname>Mora</surname><given-names>L.</given-names></name><name><surname>Fraser</surname><given-names>P.D.</given-names></name><name><surname>Aristoy</surname><given-names>M.C.</given-names></name><name><surname>Toldrá</surname><given-names>F.</given-names></name></person-group><article-title>Identification of novel antioxidant peptides generated in Spanish dry-cured ham</article-title><source>Food Chem.</source><year>2013</year><volume>138</volume><fpage>1282</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2012.10.133</pub-id><pub-id pub-id-type="pmid">23411244</pub-id></element-citation></ref><ref id="B25-nutrients-09-00321"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blann</surname><given-names>A.D.</given-names></name><name><surname>Nadar</surname><given-names>S.K.</given-names></name><name><surname>Lip</surname><given-names>G.Y.</given-names></name></person-group><article-title>The adhesion molecule P-selectin and cardiovascular disease</article-title><source>Eur. Heart J.</source><year>2003</year><volume>24</volume><fpage>2166</fpage><lpage>2179</lpage><pub-id pub-id-type="doi">10.1016/j.ehj.2003.08.021</pub-id><pub-id pub-id-type="pmid">14659768</pub-id></element-citation></ref><ref id="B26-nutrients-09-00321"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kling</surname><given-names>D.</given-names></name><name><surname>Stucki</surname><given-names>C.</given-names></name><name><surname>Kronenberg</surname><given-names>S.</given-names></name><name><surname>Tuerck</surname><given-names>D.</given-names></name><name><surname>Rhéaume</surname><given-names>E.</given-names></name><name><surname>Tardif</surname><given-names>J.C.</given-names></name><name><surname>Gaudreault</surname><given-names>J.</given-names></name><name><surname>Schmit</surname><given-names>C.</given-names></name></person-group><article-title>Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab—Preclinical and clinical studies</article-title><source>Thromb. Res.</source><year>2013</year><volume>131</volume><fpage>401</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2013.02.020</pub-id><pub-id pub-id-type="pmid">23522853</pub-id></element-citation></ref><ref id="B27-nutrients-09-00321"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konić-Ristić</surname><given-names>A.</given-names></name><name><surname>Srdić-Rajić</surname><given-names>T.</given-names></name><name><surname>Kardum</surname><given-names>N.</given-names></name><name><surname>Aleksić-Veličković</surname><given-names>V.</given-names></name><name><surname>Kroon</surname><given-names>P.A.</given-names></name><name><surname>Hollands</surname><given-names>W.J.</given-names></name><name><surname>Needs</surname><given-names>P.W.</given-names></name><name><surname>Boyko</surname><given-names>N.</given-names></name><name><surname>Hayran</surname><given-names>O.</given-names></name><name><surname>Jorjadze</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>Effects of bioactive-rich extracts of pomegranate, persimmon, nettle, dill, kale and Sideritis and isolated bioactives on arachidonic acid induced markers of platelet activation and aggregation</article-title><source>J. Sci. Food. Agric.</source><year>2013</year><volume>93</volume><fpage>3581</fpage><lpage>3587</lpage><pub-id pub-id-type="doi">10.1002/jsfa.6328</pub-id><pub-id pub-id-type="pmid">23900938</pub-id></element-citation></ref><ref id="B28-nutrients-09-00321"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shantsila</surname><given-names>E.</given-names></name><name><surname>Wrigley</surname><given-names>B.</given-names></name><name><surname>Tapp</surname><given-names>L.</given-names></name><name><surname>Apostolakis</surname><given-names>S.</given-names></name><name><surname>Montoro-Garcia</surname><given-names>S.</given-names></name><name><surname>Drayson</surname><given-names>M.T.</given-names></name><name><surname>Lip</surname><given-names>G.Y.</given-names></name></person-group><article-title>Immunophenotypic characterization of human monocyte subsets: Possible implications for cardiovascular disease pathophysiology</article-title><source>J. Thromb. Haemost.</source><year>2011</year><volume>9</volume><fpage>1056</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2011.04244.x</pub-id><pub-id pub-id-type="pmid">21342432</pub-id></element-citation></ref><ref id="B29-nutrients-09-00321"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canton</surname><given-names>J.</given-names></name><name><surname>Neculai</surname><given-names>D.</given-names></name><name><surname>Grinstein</surname><given-names>S.</given-names></name></person-group><article-title>Scavenger receptors in homeostasis and immunity</article-title><source>Nat. Rev. Immunol.</source><year>2013</year><volume>13</volume><fpage>621</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/nri3515</pub-id><pub-id pub-id-type="pmid">23928573</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="nutrients-09-00321-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Gating strategy to identify the three peripheral blood monocyte subsets (Mon1, Mon2 and Mon3). (<bold>A</bold>) FSC/SSC-dotplot was set to identify leukocytes and select lymphocytes; (<bold>B</bold>) Leukocytes were plotted in a SSC/CD14-dotplot to select high-SSC cells as Neutrophils+Eosinophils and intermedia-SSC and CD14++/+/− as Monocytes; (<bold>C</bold>) Leukocytes were also plotted in a CD14/CD16-dotplot to select Eosinophils (auto-florescent cells) and Monocyte+Neutrophils, clearly separated from the rest of the blood cell subsets. Logical combination of these gates allowed discrimination between Lymphocytes, Monocytes, Neutrophils and Esosinophils; (<bold>D</bold>) To identify the three monocyte subsets, a CD14/CD16 dotplot was used: Mon1 (CD14++CD16−, red), Mon2 (CD14++CD16+, green) and Mon3 (CD14+CD16++, blue); (<bold>E</bold>) Zoom area of mononuclear cells showing the three monocytes subsets clearly differentiated from lymphocytes and neutrophils.</p></caption><graphic xlink:href="nutrients-09-00321-g001"></graphic></fig><fig id="nutrients-09-00321-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Mean change relative to baseline time in soluble plasmatic marker levels in the interventional and control groups. The values were compared after participants had ingested 80 g/day of dry-cured ham or 100 g/day of cooked ham (<italic>n</italic> = 38) for 4 weeks (+95% confidence interval).</p></caption><graphic xlink:href="nutrients-09-00321-g002"></graphic></fig><fig id="nutrients-09-00321-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Mean change relative to baseline time in platelet and monocyte activation markers. The values were compared after participants had ingested 80 g/day of dry-cured ham (<italic>n</italic> = 21) for 4 weeks (+95% confidence interval).</p></caption><graphic xlink:href="nutrients-09-00321-g003"></graphic></fig><table-wrap id="nutrients-09-00321-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-09-00321-t001_Table 1</object-id><label>Table 1</label><caption><p>Analysis of Active Biopeptides in the Meat Products.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Biopeptides</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dry-Cured Ham</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cooked Ham</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">KAAAAP</td><td align="center" valign="middle" rowspan="1" colspan="1"></td><td align="center" valign="middle" rowspan="1" colspan="1">N.D.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AAPLAP</td><td align="center" valign="middle" rowspan="1" colspan="1">Identified</td><td align="center" valign="middle" rowspan="1" colspan="1">N.D.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">KPVAAP</td><td align="center" valign="middle" rowspan="1" colspan="1">Identified</td><td align="center" valign="middle" rowspan="1" colspan="1">N.D.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VPPAK</td><td align="center" valign="middle" rowspan="1" colspan="1">Identified</td><td align="center" valign="middle" rowspan="1" colspan="1">N.D.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">KPGRP</td><td align="center" valign="middle" rowspan="1" colspan="1">Identified</td><td align="center" valign="middle" rowspan="1" colspan="1">N.D.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IAGRP</td><td align="center" valign="middle" rowspan="1" colspan="1">N.D.</td><td align="center" valign="middle" rowspan="1" colspan="1">N.D.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PAAPPK</td><td align="center" valign="middle" rowspan="1" colspan="1">Identified</td><td align="center" valign="middle" rowspan="1" colspan="1">N.D.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TGLKP</td><td align="center" valign="middle" rowspan="1" colspan="1">N.D.</td><td align="center" valign="middle" rowspan="1" colspan="1">N.D.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AAATP</td><td align="center" valign="middle" rowspan="1" colspan="1">Identified</td><td align="center" valign="middle" rowspan="1" colspan="1">N.D.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KAAAATP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.D.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.D.</td></tr></tbody></table><table-wrap-foot><fn><p>N.D.: not detected.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-09-00321-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-09-00321-t002_Table 2</object-id><label>Table 2</label><caption><p>Clinical Characteristics of Healthy Volunteers with Normal-High Hypertension.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 38</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Volunteers</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age </td><td align="center" valign="middle" rowspan="1" colspan="1">44.3 ± 5.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gender (male)</td><td align="center" valign="middle" rowspan="1" colspan="1">82%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BMI, (kg/m<sup>2</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">27.02 ± 3.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fat content, %</td><td align="center" valign="middle" rowspan="1" colspan="1">25.08 ± 7.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Systolic BP, mmHg</td><td align="center" valign="middle" rowspan="1" colspan="1">137.4 ± 10.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diastolic BP, mmHg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80.0 ± 5.8</td></tr></tbody></table><table-wrap-foot><fn><p>BMI: Body Mass Index; BP: Blood Pressure.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-09-00321-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-09-00321-t003_Table 3</object-id><label>Table 3</label><caption><p>Plasmatic Parameters with Volunteers in Both Trial Arms (Mean Difference After (1) Dry-Cured Ham Intake, (2) Cooked Ham and (1–2) Difference).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>n</italic> = 38</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Period of Intervention</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Mean Difference</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Confidence Interval</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>p</italic> Value</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low 95%</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Upp 95%</th></tr></thead><tbody><tr><td colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1"><italic>Plasmatic markers, ELISA</italic></td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">P-selectin, ng/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">(1) Dry-cured</td><td align="center" valign="middle" rowspan="1" colspan="1">−5.00</td><td align="center" valign="middle" rowspan="1" colspan="1">−8.19</td><td align="center" valign="middle" rowspan="1" colspan="1">−1.80</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003513</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(2) Control</td><td align="center" valign="middle" rowspan="1" colspan="1">−1.31</td><td align="center" valign="middle" rowspan="1" colspan="1">−4.60</td><td align="center" valign="middle" rowspan="1" colspan="1">2.10</td><td align="center" valign="middle" rowspan="1" colspan="1">0.461629</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1)–(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−3.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−7.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.062522</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VCAM-1, ng/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">(1) Dry-cured</td><td align="center" valign="middle" rowspan="1" colspan="1">3.23</td><td align="center" valign="middle" rowspan="1" colspan="1">−17.97</td><td align="center" valign="middle" rowspan="1" colspan="1">24.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.769504</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(2) Control</td><td align="center" valign="middle" rowspan="1" colspan="1">3.41</td><td align="center" valign="middle" rowspan="1" colspan="1">−19.33</td><td align="center" valign="middle" rowspan="1" colspan="1">26.15</td><td align="center" valign="middle" rowspan="1" colspan="1">0.772709</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1)–(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−25.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.988745</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">MCP-1, pg/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">(1) Dry-cured</td><td align="center" valign="middle" rowspan="1" colspan="1">5.45</td><td align="center" valign="middle" rowspan="1" colspan="1">−8.35</td><td align="center" valign="middle" rowspan="1" colspan="1">19.25</td><td align="center" valign="middle" rowspan="1" colspan="1">0.448144</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(2) Control</td><td align="center" valign="middle" rowspan="1" colspan="1">−14.39</td><td align="center" valign="middle" rowspan="1" colspan="1">−29.20</td><td align="center" valign="middle" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.064524</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1)–(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.023489</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">hs-IL6, pg/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">(1) Dry-cured</td><td align="center" valign="middle" rowspan="1" colspan="1">−0.60</td><td align="center" valign="middle" rowspan="1" colspan="1">−1.15</td><td align="center" valign="middle" rowspan="1" colspan="1">−0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.037294</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(2) Control</td><td align="center" valign="middle" rowspan="1" colspan="1">−0.39</td><td align="center" valign="middle" rowspan="1" colspan="1">−0.96</td><td align="center" valign="middle" rowspan="1" colspan="1">0.19</td><td align="center" valign="middle" rowspan="1" colspan="1">0.199947</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1)–(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.049448</td></tr></tbody></table><table-wrap-foot><fn><p>BMI: Body Mass Index; VCAM-1: Vascular Cell Adhesion Molecule 1; MCP-1: Monocyte Chemoattractant Protein-1; hs-IL6: high-sensitivity Interleukin 6.</p></fn></table-wrap-foot></table-wrap><table-wrap id="nutrients-09-00321-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">nutrients-09-00321-t004_Table 4</object-id><label>Table 4</label><caption><p>Cellular Parameters of the Volunteers (Baseline and Mean Difference after Consuming Dry-Cured Ham for 4 Weeks).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>n</italic> = 21</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Baseline (before Dry-Cured Ham)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Mean Difference</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Confidence Interval</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic>p</italic> Value</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low 95%</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Upp 95%</th></tr></thead><tbody><tr><td colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1"><italic>Platelet activation markers</italic></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">P-selectin expression, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">492.67</td><td align="center" valign="middle" rowspan="1" colspan="1">−55.24</td><td align="center" valign="middle" rowspan="1" colspan="1">−76.32</td><td align="center" valign="middle" rowspan="1" colspan="1">−34.16</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000272</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PAC-1 binding, MFI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">426.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−26.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.447</td></tr><tr><td colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1"><italic>Monocyte activation markers (n = 21)</italic></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mon1_ICAM-1R, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">3799.22</td><td align="center" valign="middle" rowspan="1" colspan="1">552.94</td><td align="center" valign="middle" rowspan="1" colspan="1">−484.15</td><td align="center" valign="middle" rowspan="1" colspan="1">1590.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.275</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mon2_ICAM-1R, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">6325.33</td><td align="center" valign="middle" rowspan="1" colspan="1">−49.33</td><td align="center" valign="middle" rowspan="1" colspan="1">−989.93</td><td align="center" valign="middle" rowspan="1" colspan="1">891.26</td><td align="center" valign="middle" rowspan="1" colspan="1">0.912</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mon3_ICAM-1R, MFI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4579.78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1114.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−113.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2343.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.072</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mon1_VCAM-1R, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">672.70</td><td align="center" valign="middle" rowspan="1" colspan="1">643.25</td><td align="center" valign="middle" rowspan="1" colspan="1">222.89</td><td align="center" valign="middle" rowspan="1" colspan="1">1063.61</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00480</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mon2_VCAM-1R, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">1243.75</td><td align="center" valign="middle" rowspan="1" colspan="1">3022.30</td><td align="center" valign="middle" rowspan="1" colspan="1">1453.88</td><td align="center" valign="middle" rowspan="1" colspan="1">4590.72</td><td align="center" valign="middle" rowspan="1" colspan="1">0.00075</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mon3_VCAM-1R, MFI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2048.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1917.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">397.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3438.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01629</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mon1_CXCR4, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">1152.70</td><td align="center" valign="middle" rowspan="1" colspan="1">1019.90</td><td align="center" valign="middle" rowspan="1" colspan="1">545.43</td><td align="center" valign="middle" rowspan="1" colspan="1">1494.38</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0000713 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mon2_CXCR4, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">2415.00</td><td align="center" valign="middle" rowspan="1" colspan="1">4244.17</td><td align="center" valign="middle" rowspan="1" colspan="1">1313.45</td><td align="center" valign="middle" rowspan="1" colspan="1">7174.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002603 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mon3_CXCR4, MFI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2215.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9601.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1498.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17,704.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0002743 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mon1_CD163, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">1376.20</td><td align="center" valign="middle" rowspan="1" colspan="1">340.70</td><td align="center" valign="middle" rowspan="1" colspan="1">−70.88</td><td align="center" valign="middle" rowspan="1" colspan="1">752.28</td><td align="center" valign="middle" rowspan="1" colspan="1">0.098</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mon2_CD163, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">1838.90</td><td align="center" valign="middle" rowspan="1" colspan="1">164.94</td><td align="center" valign="middle" rowspan="1" colspan="1">−392.83</td><td align="center" valign="middle" rowspan="1" colspan="1">722.70</td><td align="center" valign="middle" rowspan="1" colspan="1">0.540</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mon3_CD163, MFI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2606.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−1016.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−1325.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−707.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0000024</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mon1_TLR4, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">1050.57</td><td align="center" valign="middle" rowspan="1" colspan="1">261.05</td><td align="center" valign="middle" rowspan="1" colspan="1">−44.91</td><td align="center" valign="middle" rowspan="1" colspan="1">567.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0411524 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mon2_TLR4, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">1915.72</td><td align="center" valign="middle" rowspan="1" colspan="1">2061.10</td><td align="center" valign="middle" rowspan="1" colspan="1">52.87</td><td align="center" valign="middle" rowspan="1" colspan="1">4069.33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0239622 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mon3_TLR4, MFI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1611.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3266.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">468.86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6063.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0082297 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mon1_IL6R, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">576.45</td><td align="center" valign="middle" rowspan="1" colspan="1">−24.60</td><td align="center" valign="middle" rowspan="1" colspan="1">−85.34</td><td align="center" valign="middle" rowspan="1" colspan="1">36.14</td><td align="center" valign="middle" rowspan="1" colspan="1">0.406</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mon2_IL6R, MFI</td><td align="center" valign="middle" rowspan="1" colspan="1">1186.40</td><td align="center" valign="middle" rowspan="1" colspan="1">−332.05</td><td align="center" valign="middle" rowspan="1" colspan="1">−674.78</td><td align="center" valign="middle" rowspan="1" colspan="1">10.68</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0568</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mon3_IL6R, MFI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3820.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−1475.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−2074.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−877.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0000632</td></tr></tbody></table><table-wrap-foot><fn><p>ICAM-1R: Intercellular Adhesion Molecule-1 Receptor; VCAM-1R: Vascular Cell Adhesion Molecule-1 Receptor; TLR4: Toll-Like Receptor 4; IL6R: Interleukin 6 Receptor; MFI: Mean Fluorescence Intensity. * Data were log transformed before analysis.</p></fn></table-wrap-foot></table-wrap></floats-group></article>